Overview

It is estimated that over 1,000 clinical candidate proteins and peptides are currently being investigated. In addition, 140 therapeutic proteins have been approved and 500 are in clinical trials, and it is expected that at least 50 biotherapeutics will come on to the market over the next few years. Furthermore, by 2010 nearly 50% of new pharmaceuticals are forecasted to have originated from biotechnology companies.

Many of these biotherapeutics are produced using technologically advanced microbial and mammalian cell biosystems. These cell-based, protein manufacturing technologies offer many advantages. The use of microbes for human applications is decades old, but the advent of genetic engineering provided the means to produce recombinant proteins in bacteria and yeast, making them productive bioreactors.

Using our extensive technical expertise and world class facilities, Angel Biotechnology is able to provide a highly integrated array of services to support the development of a biopharmaceutical. These range from strain creation and development, through process development and scale up, to cGMP manufacture.

Thus, we can produce recombinant protein products from microbial or mammalian cell sources to provide material for preclinical through to Phase II and Phase III clinical efficacy testing.